OTCMKTS:ACUR Acura Pharmaceuticals (ACUR) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 10:29 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and TrendsSEC Filings About Acura Pharmaceuticals Stock (OTCMKTS:ACUR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Acura Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.0001▼$0.01Volume500 shsAverage Volume3,315 shsMarket Capitalization$6.67 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Acura Pharmaceuticals, Inc. was a specialty pharmaceutical company focused on developing technologies intended to reduce the potential for abuse of prescription medicines. Its primary platform, Aversion, was designed to make certain opioid formulations more difficult to manipulate for misuse, including by crushing, snorting or dissolving the product for injection. The company’s principal commercial product was Oxecta, an immediate-release oxycodone hydrochloride tablet approved by the U.S. Food and Drug Administration in 2011 for the management of acute moderate-to-severe pain when treatment with an opioid was appropriate. Oxecta incorporated Acura’s Aversion technology and was marketed in the United States. Acura’s business was principally focused on the U.S. prescription pharmaceutical market, with an emphasis on licensing, developing and commercializing abuse-deterrent drug-delivery technologies. Publicly available information about the company’s later operations, current leadership and ongoing commercial activities is limited.AI Generated. May Contain Errors. Read More Receive ACUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acura Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACUR Stock News HeadlinesAcura Pharmaceuticals Secures New Loans Amid Bankruptcy RiskOctober 6, 2026 | tipranks.comAcura Pharmaceuticals Discloses Major SEC Filing DelaysAugust 26, 2026 | tipranks.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 15 at 1:00 AM | Base Camp Trading (Ad)Acura Pharmaceuticals Secures Loan Amid Going-Concern RisksAugust 20, 2026 | tipranks.comAcura Pharmaceuticals Secures New Loan Amid Liquidity StrainJuly 24, 2026 | tipranks.comAcura Pharmaceuticals Extends Maturity of Key Secured NoteJuly 1, 2026 | theglobeandmail.comAcura Pharmaceuticals Flags Ongoing SEC Filing DelaysMay 13, 2026 | tipranks.comAcura Pharmaceuticals Secures Insider Loans Amid Liquidity StrainMay 7, 2026 | tipranks.comSee More Headlines ACUR Stock Analysis - Frequently Asked Questions How have ACUR shares performed this year? Acura Pharmaceuticals' stock was trading at $0.0005 at the start of the year. Since then, ACUR stock has decreased by 80.0% and is now trading at $0.0001. How were Acura Pharmaceuticals' earnings last quarter? Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) released its quarterly earnings data on Friday, February, 28th. The specialty pharmaceutical company reported $0.00 earnings per share for the quarter. The specialty pharmaceutical company had revenue of $1.32 million for the quarter. Does Acura Pharmaceuticals have any subsidiaries? The following companies are subsidiaries of Acura Pharmaceuticals: Acura Pharmaceutical Technologies Inc.. How do I buy shares of Acura Pharmaceuticals? Shares of ACUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Acura Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acura Pharmaceuticals investors own include Cardiff Oncology (TROV), Eldorado Gold (EGO), American Eagle Outfitters (AEO), BlackBerry (BB), Advanced Micro Devices (AMD), Anika Therapeutics (ANIK) and Broadcom (AVGO). Company Calendar Last Earnings2/28/2020Today10/15/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ACUR Previous SymbolNASDAQ:ACUR CIK786947 Webwww.acurapharm.com Phone(847) 705-7709Fax847-705-5399Employees9Year Founded1935Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares66,650,000Free Float53,186,000Market Cap$6.67 thousand OptionableNot Optionable Beta-13.15 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (OTCMKTS:ACUR) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acura Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acura Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
